U266 cells treated with NPI-0052, thalidomide, and bortezomib alone or in combination
| NPI-0052, nM . | NPI-0052, % apoptosis . | Thalidomide, % apoptosis . | Bortezomib, % apoptosis . | ||
|---|---|---|---|---|---|
| 5 μg/mL . | 10 μg/mL . | 10 nM . | 20 nM . | ||
| 0 | 1.3 ± 0.6 | 6 ± 1 | 11.3 ± 1.5 | 9 ± 1 | 18.7 ± 1.5 |
| 50 | 3 ± 1 | 34 ± 3.6 | 82.3 ± 3.1 | 25 ± 2.6 | 56 ± 2.6 |
| 100 | 20.7 ± 4 | 57 ± 3.6 | 99.7 ± 0.6 | 52.7 ± 2.5 | 90.3 ± 1.5 |
| NPI-0052, nM . | NPI-0052, % apoptosis . | Thalidomide, % apoptosis . | Bortezomib, % apoptosis . | ||
|---|---|---|---|---|---|
| 5 μg/mL . | 10 μg/mL . | 10 nM . | 20 nM . | ||
| 0 | 1.3 ± 0.6 | 6 ± 1 | 11.3 ± 1.5 | 9 ± 1 | 18.7 ± 1.5 |
| 50 | 3 ± 1 | 34 ± 3.6 | 82.3 ± 3.1 | 25 ± 2.6 | 56 ± 2.6 |
| 100 | 20.7 ± 4 | 57 ± 3.6 | 99.7 ± 0.6 | 52.7 ± 2.5 | 90.3 ± 1.5 |
Data shown are means plus or minus the standard deviation. Cells (106/mL) were treated as in Table 1.